MedPath

Hikma Labs Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

99

Active:0
Completed:98

Trial Phases

5 Phases

Early Phase 1:6
Phase 1:10
Phase 3:1
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (99 trials with phase data)• Click on a phase to view related trials

Not Applicable
81 (81.8%)
Phase 1
10 (10.1%)
Early Phase 1
6 (6.1%)
Phase 3
1 (1.0%)
Phase 4
1 (1.0%)

Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate

Not Applicable
Completed
Conditions
Asthma
Interventions
First Posted Date
2016-01-07
Last Posted Date
2018-01-23
Lead Sponsor
Roxane Laboratories
Target Recruit Count
1430
Registration Number
NCT02649478
Locations
🇺🇸

Roxane Laboratories Research Site #30, Glendale, Arizona, United States

🇺🇸

Roxane Laboratories Research Site #46, Phoenix, Arizona, United States

🇺🇸

Roxane Laboratories Research Site #1, Surprise, Arizona, United States

and more 97 locations

Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions

Early Phase 1
Completed
Conditions
Dry Mouth
Interventions
First Posted Date
2013-07-19
Last Posted Date
2018-01-23
Lead Sponsor
Roxane Laboratories
Target Recruit Count
26
Registration Number
NCT01903122
Locations
🇺🇸

Novum Pharmaceutical Research Services, Las Vegas, Nevada, United States

Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions

Early Phase 1
Completed
Conditions
Dry Mouth
Interventions
First Posted Date
2013-07-19
Last Posted Date
2018-01-23
Lead Sponsor
Roxane Laboratories
Target Recruit Count
27
Registration Number
NCT01903109
Locations
🇺🇸

Novum Pharmaceutical Research Services, Las Vegas, Nevada, United States

Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fed Conditions

Not Applicable
Completed
Conditions
Hypertension
Interventions
First Posted Date
2012-10-23
Last Posted Date
2018-01-23
Lead Sponsor
Roxane Laboratories
Target Recruit Count
34
Registration Number
NCT01712100
Locations
🇺🇸

Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research), San Antonio, Texas, United States

Crossover Bioequivalence Study of Irbesartan HCTZ 300/25 mg Tablets Under Fasted Conditions

Not Applicable
Completed
Conditions
Hypertension
Interventions
First Posted Date
2012-10-23
Last Posted Date
2018-01-23
Lead Sponsor
Roxane Laboratories
Target Recruit Count
37
Registration Number
NCT01712139
Locations
🇺🇸

Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research), San Antonio, Texas, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 20
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.